Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by Cantor Fitzgerald

Humacyte (NASDAQ:HUMAGet Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $7.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 135.69% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target on shares of Humacyte in a research report on Tuesday, March 26th. Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Monday, March 25th. Finally, HC Wainwright began coverage on shares of Humacyte in a research report on Monday, December 11th. They set a “buy” rating and a $6.00 price target on the stock.

Read Our Latest Stock Report on HUMA

Humacyte Stock Down 1.3 %

HUMA stock opened at $2.97 on Monday. The company has a current ratio of 6.79, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average is $3.56 and its 200 day moving average is $2.96. The stock has a market cap of $347.07 million, a price-to-earnings ratio of -2.78 and a beta of 1.46. Humacyte has a 1-year low of $1.96 and a 1-year high of $5.60.

Humacyte (NASDAQ:HUMAGet Free Report) last issued its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the prior year, the firm earned ($0.21) EPS. Sell-side analysts predict that Humacyte will post -0.94 EPS for the current fiscal year.

Institutional Trading of Humacyte

Institutional investors have recently made changes to their positions in the stock. Ensign Peak Advisors Inc purchased a new stake in shares of Humacyte during the first quarter valued at approximately $56,000. American International Group Inc. purchased a new stake in shares of Humacyte during the second quarter valued at approximately $27,000. Tower Research Capital LLC TRC boosted its stake in shares of Humacyte by 261.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after purchasing an additional 6,504 shares during the period. UBS Group AG boosted its stake in shares of Humacyte by 92.0% during the third quarter. UBS Group AG now owns 9,827 shares of the company’s stock valued at $32,000 after purchasing an additional 4,710 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. purchased a new stake in Humacyte in the fourth quarter worth $28,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Featured Articles

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.